CNBX Pharmaceuticals
Cnnabinoid-based Cancer Therapies
Company Overview
Snapshot
Founded in January 2004 by Eyal Ballan, Zohar Koren, and Itamar Borochov, CNBX Pharmaceuticals operates with 1–10 employees. The company became public on OTC in September 2017, marking a significant milestone in its corporate trajectory.
Business overview
CNBX Pharmaceuticals is a Health Tech & Life Sciences company focused on developing cannabinoid-based cancer therapies. The company utilizes a platform that integrates novel drug-screening tools and artificial intelligence to create personalized treatments. By assessing effectiveness on an individual patient basis, CNBX Pharmaceuticals aims to integrate cannabinoids into future cancer therapy, operating within the Pharma & Medical Biotechnology and Medical Cannabis sectors.
Strategic signal
In October 2022, CNBX Pharmaceuticals' patent application, "Composition and Method for Treating Cancer with Cannabinoids," entered the national phase in the US and Israel. This development signals the company's progress in securing intellectual property for its core technology, indicating a strategic focus on formalizing its therapeutic approaches and expanding its market reach for cannabinoid-based cancer treatments.
Company Intelligence Q&A
- When did CNBX Pharmaceuticals become a public company?
- CNBX Pharmaceuticals became public on OTC in September 2017.
- What was a key intellectual property development for CNBX Pharmaceuticals?
- In October 2022, CNBX Pharmaceuticals' patent application for "Composition and Method for Treating Cancer with Cannabinoids" entered the national phase in the US and Israel.
- What was the company's name change in March 2022?
- In March 2022, Cannabics Pharmaceuticals changed its name to CNBX Pharmaceuticals.
- What research findings did Cannabics Pharmaceuticals announce in May 2020?
- In May 2020, Cannabics Pharmaceuticals showed that specific cultivars were identified to have positive anti-tumor effects on gastric adenocarcinoma.
- What strategic move did Cannabics Pharmaceuticals make regarding Israel's medical cannabis export approval?
- In June 2020, Cannabics Pharmaceuticals announced plans to capitalize on Israel's final approval for the export of medical cannabis.